2017's Top Biopharma Deal-makers
A co-development and co-commercialization agreement between AstraZeneca and Merck, one of the largest of 2017, continued the dominance of immuno-oncology in partnerships. There was significant consolidation in the consumer health industry, coupled with CVS and Aetna's major move to change health care delivery.
You may also be interested in...
Catenion updates its annual list of the year's top pharma R&D performers. R&D productivity declined for the first time since 2014. Mid pharmas continue to dominate the top 10, but big pharmas are making inroads.
GSK's various thwarted efforts to boost productivity through R&D revamps begs the question whether big pharma should be trying to do in-house discovery and early development at all.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.